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Interleukin-33 (IL-33) is a mucosal alarmin belonging to the IL-1 cytokine family and is
now recognized to have a key role in innate and adaptive immunity, contributing to tissue
homeostasis and response to environmental stresses. In addition, IL-33 has also been
shown towork as a positive regulator that initiates andmaintains a Th2 immune response.
In the context of pregnancy, it has been recently demonstrated that upon certain stress
conditions, such as an infection induced inflammation, IL-33 is released from the uterine
mucosa and triggers decidual B cells to produce anti-inflammatory molecules, which in
turn restore immune homeostasis and prevents the development of preterm birth. In this
study we therefore performed a detailed characterization of IL-33 receptor (Il1rl1 or ST2)
expression in B cells during normal pregnancy, as well as in a mouse model of preterm
birth. We observed that splenic B cells significantly up-regulate the expression of Il1rl1
during pregnancy and identified the B1 B cell population as the main ST2-expressing B
cell subset. A further kinetic analysis showed that percentages of ST2-expressing B1 B
cells are significantly augmented on days 12 and 14 of pregnancy, both in the spleen
and peritoneal cavity of pregnant mice, and then drop toward the end of pregnancy
to the levels observed in non-pregnant animals. Furthermore, using a mouse model
of LPS-induced preterm birth, we demonstrated that not only are the percentages of
ST2-expressing B1 B cells significantly enlarged in the spleen during the acute phase
of preterm birth, but decidual B cells also significantly up-regulate ST2 expression as
compared to term-pregnant mice. Overall, our results suggest a functional role of ST2
expression in B cells during pregnancy and reinforce the importance of the IL-33/ST2
axis in B cells as a critical mechanism to control inflammation-induced preterm birth.
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INTRODUCTION
Successful pregnancies in mammals rely on the capacity of the
maternal immune system to finely regulate an immune balance
between immune tolerance, to avoid rejection of the semi-
allogeneic fetus, and immune activation, to protect the mother
against infection. Different immune mechanisms, including
innate as well as adaptive immunity, have been implicated
in this phenomenon; failures in the acquisition or disruption
of this intricate immune balance might lead to pregnancy
complications (1–11).
Our laboratory and others have extensively demonstrated that
the B cell compartment undergoes significant adaptations during
pregnancy, apparently to support the acceptance of the semi-
allogeneic fetus (12–19) and to avoid the occurrence of immune
mediated pregnancy disorders, like preterm birth (PTB) among
others (15, 19–30). Moreover, it has recently been demonstrated
that decidual B cells, through a mechanism involving IL-33,
can control inflammation induced by bacterial components and
significantly reduce the occurrence of PTB (31).
IL-33 is a member of the IL-1 family of cytokines (32–34),
produced and released by damaged or necrotic endothelial and
epithelial cells. IL-33 functions as an alarm signal (alarmin)
released upon cell injury or tissue damage to alert immune cells
expressing the IL-33 receptor (ST2) (35–37). Indeed, the main
targets of IL-33 are tissue–resident immune cells, including B
cells (38).
In order to get a deeper understanding of the immune
mechanisms involved in normal pregnancy and in PTB, in
the present study, we performed for the first time a detailed
immunophenotyping study of the dynamics of ST2 expression in
different B cell subsets during normal pregnancy, as well as in a
mouse model of LPS-induced PTB.
MATERIALS AND METHODS
Animals
Six to eight week-old C57B6/J females and male mice were
purchased from the Central Animal Facility of the Faculty of
Natural Sciences, Buenos Aires University. Mice were kept in
our animal facility under optimal conditions in a 12L:12D
cycle and fed ad libitum. Animal experiments were carried
out according to institutional guidelines after approval by the
Institutional Commission for the Care and Use of Laboratory
Animals (CICUAL 2248).
Two C57BL6/J females were placed with a BALB/c male in the
same cage and checked daily for vaginal plugs. The day vaginal
plug was detected was considered day 0 of pregnancy. Pregnant
females were separated from the males and euthanized at day 12
post-plug (dpp), 14 dpp, or 16 dpp. As control, non-pregnant
(NP) age-matched virgin C57BL6/J females were included.
Mouse Model of Preterm Birth
BALB/c pregnant C57B6/J females were challenged on day
16 of gestation with an IP injection of LPS (10 µg/mice), a
dose that induces 100% of preterm birth in mice (unpublished
data from our laboratory). PTB was defined as the delivery
of a pup occurring between 24 and 48 h post LPS injection.
To analyze ST2 expression in splenic and decidual B cells
during the acute phase of PTB, animals were sacrificed 5 h after
LPS challenge.
Antibodies and Reagents
The following anti-mouse fluorescently labeled antibodies
were used:
CD45 (clone 30-F11) B220 (clone RA3-6B2), CD19 (clone
6D5), CD23 (clone B3B4), CD21 (clone 7E9), CD5 (clone 53-
7.3), and ST2 (clone DIH9). All antibodies were purchased from
Biolegend USA.
Cell Preparation and Flow Cytometry
For flow cytometry analysis, single-cell suspensions were
obtained from different tissues following previously described
procedures (17, 18, 39). Briefly, spleens were crushed in a 100-
µm cell strainer to obtain a single cell suspension and red blood
cells were lysed in lysis buffer 1X (NH4Cl 150mM, KHCO3
10mM, and EDTA 1mM) for 5min. Peritoneal cell suspensions
were obtained by peritoneal washouts with 10ml PBS+BSA 3%
(w/v). Cell isolation from decidual tissue was performed using
a commercial enzymatic solution (StemPro Accutase, Gibco).
Briefly, decidual tissues were dissociated in 500 µl of enzymatic
solution with sterile scissors for 2min on ice until solution
was finely minced. Homogenized tissues were next incubated
in enzymatic solution for 35min at 37◦C with gentle orbital
agitation (80 rpm). Dissociated tissues were filtered through a
cell strainer (100µm), washed twice with phosphate-buffered
saline (PBS, 1X), and centrifuged at 1,250 g for 10min at 4◦C.
Cell pellets were resuspended in 1ml of RPMI, loaded into
a 15-ml falcon tube containing 500 µl of fetal bovine serum
(FBS) and centrifuged at 1,100 g for 10min at room temperature.
After discarding cellular debris retained at the PBS/FBS interface,
viable cells at the bottom of the tube were resuspended in
PBS 1X.
After washing, cell suspensions were counted using a
Neubauer chamber, and 1 × 106 cells were stained for 30min
at 4 ◦C with specific labeled antibodies. Fluorescence minus one
(FMO) was used as control. Data were acquired on FACS Canto
II and BDAccuri C6 Plus (BD Biosciences) and analyzed by using
FlowJo v10 software.
RNA Isolation, cDNA Synthesis, and qPCR
Magnetically isolated splenic B cells (Pan B Cell Isolation
Kit, Miltenyi Biotec) from pregnant (day 14 of gestation)
and non-pregnant females were treated with TriFast
peqlab. RNA isolation and first-strand cDNA synthesis
(SuperScriptTM III First-Strand Synthesis System, Invitrogen)
were performed according to manufacturer’s instruction.
Primer pairs were designed using Primer Express R©
Primer Design Software v3.0 (Applied Biosystems) and
chosen to span an exon–exon junction to avoid unwanted
genomic DNA amplification. Primer sequences were
as follows:
il1rl1 Fw: CCAGTAAGTGAGACAGCAGCATTT; il1rl1
Rw: CTGTAGATACCCAGATGAAGGGCT; β-actin Fw:
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TGGAATCCTGTGGCATCCATGAAAC; Rw: TAAAACGCA
GCTCAGTAACAGTCC. All primers were purchased from
Invitrogen (Carlsbad, CA, USA). CFX96 Real-Time PCR
Detection Systems was used to perform semiquantitative qPCR
(Power SYBR Green Master Mix, Applied Biosystems) with β-
actin as housekeeping gene. Samples were amplified in duplicate
and non-template samples were used as controls. Results were
analyzed by BioRad CFX Manager 2.0. Relative expression was
calculated using the following formula:
Relative expression = 2−1CT; where 1CT = CT
gen – CT β-actin.
Statistical Analysis
Data were analyzed with PRISM software (ver. 5.01;
GraphPad). The Shapiro–Wilk test was used to test for
normality of the data. ANOVA followed by Tukey multiple
post t-test (normally distributed data) or Kruskal–Wallis
test followed by Dunn’s multiple comparisons test (non-
normally distributed data) was applied to evaluate differences
between multiple groups. Two tailed t-test (normally
distributed data) or Mann–Whitney U-test (non-normally
distributed data) were applied to compare two groups.
A p < 0.05 was considered statistically significant for
all tests.
RESULTS
Ilrl1 Gene Expression Is Significantly
Up-Regulated in Splenic B Cells During
Pregnancy
Unpublished data from a genome-wide transcriptomic profiling
performed in our laboratory showed that levels of interleukin
1 receptor-like 1 mRNA (Ilrl1) codifying for IL-33 protein
membrane receptor also known as ST2 or IL-33R were
significantly up-regulated in splenic B cells isolated from
pregnant mice on day 14 of pregnancy as compared to B cells
isolated from the spleen of control mice (NP) (Unpublished
data). Based on this data we began this work by analyzing
the expression levels of Ilrl1 in pure isolated splenic B cells
from NP and pregnant (P) mice on day 14 of pregnancy
by qPCR. As shown in Figure 1, expression levels of Ilrl1
were significantly higher in isolated splenic B cells from
pregnant mice on day 14 of pregnancy, as compared to
B cells isolated from non-pregnant (NP) controls animals
(Figure 1).
Percentages of ST2-Expressing B Cells Are
Augmented in the Spleen of Pregnant Mice
Once we confirmed that Ilrl1 is up-regulated in splenic B
cells toward mid-pregnancy, we next performed a kinetic
analysis of ST2 expression, at protein levels, in splenic B
cells through gestation. As shown in Figure 2, percentages
of ST2-expressing B220+ B cells in the spleen of pregnant
mice were significantly increased on day 12 of pregnancy
and remained significantly high on day 14 as compared
to NP control females (Figure 2). However, toward end of
FIGURE 1 | Expression levels of Il1rl1 in pure isolated B cells from pregnant
and non-pregnant mice. qPCR analysis showing significantly higher relative
expression levels of Il1rl1 normalized to β-actin, in splenic B cells isolated from
pregnant mice on day 14 of pregnancy (P, n = 8) as compared to B cells
isolated from non-pregnant (NP, n = 8) control females (6 × 10−5 ± 1 × 10−5
vs. 4 × 10−4 ± 1 × 10−4). Data is shown as mean ± SEM. **p < 0.01 as
analyzed by unpaired t-test.
pregnancy (16 dpp), percentages of ST2-expressing B220+ B
cells dropped to the levels observed in NP control mice
(Figure 2).
ST2 Is Predominantly Expressed in Splenic
B1 B Cells During Pregnancy
Next, we were interested in knowing if the increase observed
in the percentages of splenic ST2-expressing B cells during
pregnancy was homogeneously distributed through all B cell
subsets or associated with a specific B cell sub-population.
To address this, we used a well-defined splenic gating
strategy based on the expression of B cell surface markers
B220, CD21 and CD23 (40). By doing so, we analyzed the
expression of ST2 in B1 (B220lowCD23−CD21−), as well as
follicular (FO: B220+CD23hiCD21low) and marginal zone (MZ:
B220+CD23lowCD21hi) B2 B cells (Figure 3). We found that
percentages of ST2-expressing FO as well as MZ B cells were
very low (Figure 3), and no differences were observed when
comparing NP with pregnant mice on day 12 of pregnancy
(2.4 ± 0.3 vs. 2.3 ± 0.2% and 3.7 ± 0.6 vs. 1.9 ± 0.3%,
respectively). However, on day 14 of pregnancy, a modest but
significant increase of ST2 expressing FO and MZ B cells was
observed when compared to non-pregnant control mice (3.5 ±
0.2 vs. 2.3 ± 0.2% and 4.4 ± 0.7 vs. 1.9 ± 0.3%, respectively;
Figure 3). At day 16 of pregnancy, levels of ST2- expressing FO
and MZ B cells were similar to those observed in NP-control
mice (2.3 ± 0.4 vs. 2.3 ± 0.2% and 1.7 ± 0.2 vs. 1.9 ± 0.3%,
respectively). Interestingly, we detected a considerable increase
in the percentages of ST2 expressing B1 B cells in the spleen
of pregnant mice on day 12 and 14 of pregnancy as compared
to NP mice (51.9 ± 2.9% and 51.1 ± 2.3 vs. 8.4 ± 2.1%,
respectively), which was mirrored by a significant increase in ST2
mean fluorescence intensity (MFI; Supplementary Figure 1). At
day 16 of pregnancy, percentages of ST2 expressing B1 B cells as
well as ST2-MFI were similar to NP control mice (Figure 3 and
Supplementary Figure 1, respectively).
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FIGURE 2 | Kinetic analysis of ST2 expression in splenic B cells throughout pregnancy. (A) Representative pseudocolor and contour plots showing gating strategy
used to quantify percentages of ST2-expressing B cells in the spleen of pregnant and non-pregnant females. Lymphocytes were gated by FSC vs. SCC, doublets
were eliminated, and B220 was used to define total B cell population in the spleen. Fluorescence minus one (FMO) was used as control. (B) Box and whisker plots
showing percentages of ST2-expressing total B cells in the spleen of pregnant mice on day 12 (12 dpp; n = 9), 14 (14 dpp; n = 11), and 16 (16 dpp; n = 7) of
pregnancy as well as in non-pregnant control females (NP, n = 11). Data are expressed as Box and Whisker plots showing median. *p < 0.05; **p < 0.01; ***p < 0.
001; and ****p < 0.0001 as analyzed by Kruskal–Wallis test followed by Dunn’s multiple comparisons test.
Levels of ST2-Expressing B1 B Cells Are
Augmented in the Peritoneal Cavity During
Pregnancy
As peritoneal cavity is the natural reservoir of the B1 B cells, we
next analyzed the dynamic of ST2 expression in peritoneal cavity
B cells during pregnancy (Figure 4A). Similarly to what was
observed in the spleen, percentages of ST2-expressing CD19+
total B cells were significantly higher in the peritoneal cavity of
pregnant mice on days 12 and 14 of pregnancy as compared
to non-pregnant virgin females (14 ± 1.7% and 13.5 ± 1.8 vs.
5.5 ± 0.5%, respectively; Figure 4B). At day 16 of pregnancy,
percentages of ST2-expressing B cells were similar to those
observed in NP control mice (Figure 4B). Similarly, percentages
of ST2-expressing CD19+CD5+ B1 B cells were increased,
although not significantly, on day 12 of pregnancy (17.8 ± 3 vs.
8.5± 0.5%; Figure 4B) and reached statistical significance on day
14 of pregnancy, as compared to NP control mice (28.6 ± 3.7∗∗
vs. 8.5 ± 0.5%; Figure 4B). At day 16 of pregnancy, percentages
of ST2-expressing CD19+CD5+ B1 B cells were similar to those
in NP control mice (8.5± 0.5 vs. 8.5± 0.5%; Figure 4B).
Percentages of Splenic ST2-Expressing B1
B Cells Are Augmented in the Acute Phase
of LPS-Induced PTB
It has recently been demonstrated that B cells play a critical role
in protecting mice against inflammation-induced PTB through a
mechanism involving mucosal alarmin IL-33 (31). Thus, we next
analyzed the expression of ST2 in splenic B cells during the acute
phase of LPS-induced PTB (5 h after LPS challenge). As shown
in Figure 5, percentages of ST2-expressing follicular as well as
marginal zone B cells in the spleen were similar in LPS-challenged
mice (5 h after injection) compared to PBS-treated control mice
(4.2 ± 0.5 vs. 6.3 ± 0.5 and 4.7 ± 2.6 vs. 10.9 ± 2.5; Figure 5).
Remarkably, a significant expansion in the percentages of ST2-
expressing B1 B cells was observed in the spleen of LPS-induced
PTB mice, as compared to control mice (35 ± 5.6 vs. 16.7 ± 1.7;
Figure 5).
Decidual B Cells Up-Regulate ST2
Expression During the Acute Phase of PTB
It was recently demonstrated that, upon uterine stress provoked
by LPS-induced inflammation, decidual cells respond producing
IL-33, which in turn induces the production of anti-inflammatory
molecules by decidual B cells, thus preventing or limiting
induction of PTB. Hence, we next analyzed the expression of ST2
in decidual B cells during the acute phase of LPS-induced PTB.
We observed that 5 h after LPS injection, decidual
CD45+B220+ B cells express significantly higher levels of
ST2, as compared to PBS-treated pregnant mice undergoing
term pregnancies (Figure 6).
DISCUSSION
We demonstrated in this work that splenic B cells significantly
up-regulate IL-33 receptor at the RNA (Ilrl1) as well as at
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FIGURE 3 | Percentages of ST2-expressing follicular, marginal zone, and B1 B cells in the spleen of pregnant and non-pregnant mice. (A) Representative
pseudocolor and contour plots showing gating strategy used to quantify percentages of ST2-expressing follicular (FO), marginal zone (MZ), and B1 B cells in the
spleen of pregnant and non-pregnant females. Lymphocytes were gated by FSC vs. SCC, doublets were eliminated, and B220 was used to define total B cells. CD23
and CD21 markers were used to identify FO (B220+CD23hiCD21low), MZ (B220+CD23lowCD21hi), and B1 (B220lowCD23−CD21−) B cells. Fluorescence minus one
(FMO) was used as control. (B) Box and Whisker plots showing percentages of ST2-expressing FO, MZ and B1 B cells at day 12 (12 dpp; n = 9, n = 9, and n = 9,
respectively), 14 (14dpp; n = 11, n = 11, and n = 11, respectively) and 16 (16 dpp; n = 7, n = 7, and n = 7, respectively) of pregnancy as well as in non-pregnant
females (NP; n = 11, n = 11, and n = 11, respectively). Data are expressed as box and whisker plots showing median. *p < 0.05; **p < 0.01; ***p < 0.0001 as
analyzed by ANOVA followed by Tukey’s multiple comparisons test.
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FIGURE 4 | Percentages of ST2-expressing total and B1 B cells in the peritoneal cavity of pregnant and non-pregnant mice. (A) Representative pseudocolor and
contour plots showing gating strategy used to quantify percentages of ST2-expressing total CD19+ B cells as well as CD19+CD5+ B1 B cells in the peritoneal cavity
of pregnant and non-pregnant mice. Lymphocytes were gated by FSC vs. SCC, doublets were eliminated, and CD19 alone or in combination with and CD5 were
used to define total as well as B1 B cells, respectively. Fluorescence minus one (FMO) was used as control. (B) Box and whisker plots showing percentages of
ST2-expressing CD19+ B cells in peritoneal cavity of non-pregnant (NP; n = 9) and pregnant mice at day 12 (12 dpp; n = 5), 14 (14 dpp; n = 9), and 16 (16 dpp; n =
3) of pregnancy as well as percentages of ST2-expressing CD19+CD5+ B1 B cells in non-pregnant (NP; n = 9) and in pregnant mice at day 12 (12 dpp; n = 5), 14
(14 dpp; n = 9), and 16 (16 dpp; n = 3) of pregnancy. Data are expressed as box and whisker plots showing median. *p < 0.05; **p < 0.01 as analyzed by ANOVA
followed by Tukey’s multiple comparisons test.
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FIGURE 5 | Percentages of ST2-expressing follicular, marginal zone, and B1 B cells in the spleen of pregnant mice during the acute phase of LPS-induced preterm
birth. (A) Representative pseudocolor and contour plots showing gating strategy used to quantify percentages of ST2-expressing follicular (FO), marginal zone (MZ),
and B1 B cells in the acute phase of LPS-induced preterm birth and in term-pregnant control mice. Lymphocytes were gated by FSC vs. SCC, doublets were
eliminated and B220 was used to define total B cells. CD23 and CD21 markers were used to identify FO (B220+CD23hiCD21low), MZ (B220+CD23lowCD21hi) and B1
(B220lowCD23−CD21−) B cells. Fluorescence minus one (FMO) was used as control. (B) Bar graphs showing percentages of ST2-expressing FO, MZ, and B1 B cells
in preterm birth (PT; n = 6) and term birth control mice (TB; n = 6). Data are expressed as mean ± SEM. **p < 0.01 as analyzed by two-tailed unpaired t-test.
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FIGURE 6 | Expression levels of ST2 in decidual B cells during the acute phase of LPS-induced preterm birth. (A) Representative pseudocolor plots and histogram
showing gating strategy used to quantify the expression of ST2 in decidual B cells during the acute phase of LPS-induced preterm birth (PTB) and in term birth mice
(TB). Lymphocytes were gated by FSC vs. SCC and doublets were eliminated. After gating in total CD45+ leukocytes, B220 was used to identify total decidual B cells.
Fluorescence minus one (FMO) was used as control. (B) Bar graph shows median of fluorescence intensity (MFI) for ST2 in decidual B cells from TB (n = 6) and PTB
mice (n = 6). Data is expressed as mean ± SEM. *p < 0.05 as analyzed by Wilcoxon test.
the protein (ST2) levels during physiological pregnancies in
mice and identified the B1 B cell subset as the main B cell
population expressing ST2. This is in agreement with previous
publications indicating that ST2, in mice, is predominantly
expressed in B1, while almost absent in B2 B cells (38).
Furthermore, we showed that splenic as well as peritoneal
cavity ST2-expressing B1 B cells followed a unique kinetic
during pregnancy, being significantly high on days 12 and 14 of
pregnancy and then dropping toward end of pregnancy (16 dpp)
to levels observed in non-pregnant control mice. This special
pattern of expression suggests that ST2-expresssing B1 B cells
might play a differential role during specific time frames in
pregnancy. In this regard, it is well-known that after a short
period of a pro-inflammatory Th1 immune profile needed for
embryo implantation, pregnancy well-being is associated with a
shift into a Th2 anti-inflammatory status that dominates until
end of pregnancy, when a Th1 pro-inflammatory response is
required for parturition (25, 26, 41–49). As IL-33/ST2 axis was
shown to be critical in inducing and maintaining a Th2 immune
profile both in physiological and pathological settings (35, 50–
60), it is possible to speculate that expansion of ST2-expressing
B1 B cells is part of the intricate immune mechanism launched
during pregnancy to induce and maintain an anti-inflammatory
Th2 profile. Supporting this idea, we observed that toward
end of pregnancy, when a shift into Th1 profile is demanded,
percentages of ST2-expressing B1 B cells were decreased. The
decrease observed in the percentages of ST2-expressing B1 B
cells between mid- and late pregnancy is somehow in line with
previous results from our laboratory, in which we showed that
percentages and activation of B1 B cells were decreased during
late pregnancy (61). As B1 B cells are the main source of natural
antibodies, which are known to be polyreactive and potentially
auto-reactive (62), we proposed that decrease of B1 B cells
numbers and activation may represent a protective mechanism
to prevent the presence of natural and polyreactive antibodies
at the fetal–maternal interface, which would put the growing
fetus at risk. This is particularly important toward the end
of pregnancy when the process of passive immunization takes
place. Indeed, it has been shown that IL-33, thought to be ST2,
induces B1 B cell activation, leading to a rapid proliferation
and production of natural IgM (38). Besides inducing a Th2
immune response, the IL-33/ST2 axis has also been extensively
demonstrated to participates in regulating immune homeostasis
upon tissue injury (15, 33, 33, 36, 37, 63–69). In the context of
pregnancy, Huang and co-authors have recently demonstrated
that choriodecidual B1 B cells protect against inflammation-
induced PTB by producing progesterone-induced blocking factor
1 (PIBF1) in response to the mucosal alarmin IL-33 (31).
Interestingly, we observed that, despite percentages of splenic
ST2-expressing B1 B cells dropping toward end of pregnancy,
its levels are significantly increased during the acute phase of
LPS-induced PTB (5 h after LPS injection). Similarly, we also
observed that decidual B cells up-regulated ST2 expression in the
acute phase of LPS-induced PTB as compared to term-pregnant
mice. This is somehow in contradiction with data from Huang
and co-authors who showed that decidual B cells from PTB
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women express significantly lower levels of ST2 as compared
to term-pregnant women (31). This difference can easily be
explained by the fact that ST2 expression in decidual B cells
was measured in a different time frame. While Huang and co-
authors analyzed ST2 expression in B cells of PTB women after
delivery, we did this during acute phase of LPS-induced PTB.
Indeed, it is widely accepted that in order to maintain tissue
homeostasis during inflammatory or infectious insults, white
blood cells are recruited to damaged tissues where a transient
expression of ST2 is induced and responsiveness to IL-33 is
gained (70, 71).
Hence, it can be argued that upon acute inflammation induced
by microbial or microbial components such as LPS during
pregnancy, decidual B cells rapidly up-regulate ST2 expression
acquiring the capacity to respond to IL-33 produced by uterine
mucosa and doing so help to prevent or resolve inflammation
induced PTB.
Overall, data showed in this work describe for the first
time the dynamic of ST2 expression in B cells during
normal pregnancy and in preterm birth in mice. This is
a remarkable piece of information, and together with a
recent publication showing the fundamental role of decidual
B cells in preventing inflammation-induced PTB through
an IL-33 pathway (31), it places the IL-33/ST2 axis in B
cells as a novel and not-yet explored immune mechanisms
critical for safeguarding pregnancy well-being. Further studies
including human pregnancies are demanded in order to confirm
these findings.
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